# A high-grade undifferentiated prostate malignancy in a young male suggestive of male adnexal tumour of Wolffian origin – A rare case and diagnostic challenge

**Authors:** Rowan Klein Nulend, Kathleen Lockhart, Kevin Tree, Linh NK. Tran, Bashar Matti, Yelise Foon, Ali Moghimi, Daniel Wong, Jordan Butler, Lawrence HC. Kim, Audrey Wang, Manish I. Patel

PMC · DOI: 10.1016/j.eucr.2026.103359 · Urology Case Reports · 2026-01-27

## TL;DR

A rare case of aggressive prostate cancer in a young man highlights the diagnostic challenges and the importance of early multidisciplinary treatment.

## Contribution

This case report presents a rare high-grade prostatic malignancy in a young male and highlights the diagnostic and therapeutic challenges associated with such rare tumors.

## Key findings

- Prostatic malignancies in young adults are extremely rare and often present diagnostic difficulties.
- Multidisciplinary approaches and aggressive treatment can lead to remission in rare, aggressive prostate tumors.
- Current diagnostic tools struggle to classify rare tumor subtypes like male adnexal tumors of Wolffian origin.

## Abstract

We report a rare case of a high-grade, poorly differentiated prostatic malignancy in a 24-year-old, initially presenting with haematuria and urinary retention following trauma. Imaging and cystoscopy revealed a large prostate mass. Although a final histopathological diagnosis could not be definitively determined, expert review suggests this may resemble a male adnexal tumour of Wolffian origin, an extremely rare pathology. The patient underwent neoadjuvant chemotherapy, followed by radical cystoprostatectomy and adjuvant radiotherapy. He remains in remission 18 months post-treatment. This case underscores the importance of thorough investigation and multidisciplinary management of rare, aggressive prostatic tumours in young patients.

•Rare presentation – Prostatic malignancies in young adults are exceptionally uncommon. This case emphasizes the need to consider malignant pathology even in patients outside the typical demographic.•Diagnostic challenges – Despite advanced imaging, immunohistochemistry, genetic testing, and expert histopathology review, a definitive tumour subtype was difficult to establish. This underlines the limitations of current diagnostic tools in rare tumour biology.•Importance of early, multidisciplinary intervention – Prompt recognition of haematuria as a red-flag symptom, coupled with imaging, enabled early diagnosis. Aggressive multimodal therapy within a multidisciplinary framework resulted in 12-month remission.

Rare presentation – Prostatic malignancies in young adults are exceptionally uncommon. This case emphasizes the need to consider malignant pathology even in patients outside the typical demographic.

Diagnostic challenges – Despite advanced imaging, immunohistochemistry, genetic testing, and expert histopathology review, a definitive tumour subtype was difficult to establish. This underlines the limitations of current diagnostic tools in rare tumour biology.

Importance of early, multidisciplinary intervention – Prompt recognition of haematuria as a red-flag symptom, coupled with imaging, enabled early diagnosis. Aggressive multimodal therapy within a multidisciplinary framework resulted in 12-month remission.

## Full-text entities

- **Genes:** PAX2 (paired box 2) [NCBI Gene 5076] {aka FSGS7, PAPRS, PAX-2}, SF1 (splicing factor 1) [NCBI Gene 7536] {aka BBP, D11S636, MBBP, ZCCHC25, ZFM1, ZNF162}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, WT1 (WT1 transcription factor) [NCBI Gene 7490] {aka AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1}, NKX2-2 (NK2 homeobox 2) [NCBI Gene 4821] {aka NKX2.2, NKX2B}, NKX3-1 (NK3 homeobox 1) [NCBI Gene 4824] {aka BAPX2, NKX3, NKX3.1, NKX3A}, KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, PAX8 (paired box 8) [NCBI Gene 7849] {aka PAX-8}
- **Diseases:** bladder masses (MESH:D001745), sarcoma (MESH:D012509), dysuria (MESH:D053159), rhabdomyosarcoma (MESH:D012208), lymphadenopathy (MESH:D008206), ATWO (MESH:C536741), adenocarcinoma (MESH:D000230), Cancer (MESH:D009369), male adnexal tumour (MESH:D005834), Prostate Tumour (MESH:D011471), trauma (MESH:D014947), leiomyosarcoma (MESH:D007890), Necrosis (MESH:D009336), prostate (MESH:D011472), cutaneous malignancy (MESH:C562393), LUTS (MESH:D059411), Ewing sarcoma (MESH:D012512), metastases (MESH:D009362), urinary retention (MESH:D016055), pelvic pain (MESH:D017699)
- **Chemicals:** mesna (MESH:D015080), Eosin (MESH:D004801), ifosfamide (MESH:D007069), FDG (MESH:D019788), Haematoxylin (MESH:D006416), doxorubicin (MESH:D004317)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914286/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914286/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914286/full.md

---
Source: https://tomesphere.com/paper/PMC12914286